Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11389541 Sustained delivery of angiopoetin-like 3 polypeptides

Patent 11389541 was granted and assigned to Novartis on July, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Applicant

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

Cameron Chuck-munn Lee0

Christopher M. Adams0

Cornelia Jutta Forster0

Edward Charles Hall0

Jean-Baptiste Georges Armand Langlois0

Myriam April0

Nicole Gerwin0

Tanzina Fazal0

Date of Patent

July 19, 2022

Patent Application Number

16591053

Date Filed

October 2, 2019

Patent Citations

US Patent 11179442 Peptides and compositions for treatment of joint damage

0

US Patent 10239927 Peptides and compositions for treatment of joint damage

US Patent 10328126 Peptides and compositions for treatment of joint damage

0

US Patent 10533042 Peptides and compositions for treatment of joint damage

US Patent 10751417 Sustained release delivery systems comprising traceless linkers

Patent Primary Examiner

Sudhakar Katakam

CPC Code

...

Described herein are drug delivery systems for delivering biologically active agents comprising primary or secondary amines, or a ring nitrogen atom of an azaheteroaryl ring, pharmaceutically acceptable salts thereof, drug delivery reagents related thereto, pharmaceutical compositions comprising the drug delivery systems, and the use of the drug delivery systems as sustained release therapeutics.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11389541 Sustained delivery of angiopoetin-like 3 polypeptides

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool